Bonnet BioTherapeutics and Rorschach I LLC merged to form Hyperliquid Strategies

Golden Finance reports that Nasdaq-listed Sonnet BioTherapeutics, Inc. has agreed to merge with Rorschach I LLC to form Hyperliquid Strategies, Inc. This company will launch the HYPE reserve strategy, and post-transaction, the new entity is expected to hold 12.6 million HYPE tokens and $305 million in cash, with a total valuation of $888 million.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)